company background image

Vifor Pharma SWX:VIFN Stock Report

Last Price


Market Cap







26 May, 2022


Company Financials +
VIFN fundamental analysis
Snowflake Score
Future Growth4/6
Past Performance3/6
Financial Health6/6

VIFN Stock Overview

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally.

Vifor Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vifor Pharma
Historical stock prices
Current Share PriceCHF169.50
52 Week HighCHF197.20
52 Week LowCHF102.30
1 Month Change-0.47%
3 Month Change3.99%
1 Year Change31.04%
3 Year Change21.51%
5 Year Change51.34%
Change since IPO1,081.19%

Recent News & Updates

Shareholder Returns

VIFNCH PharmaceuticalsCH Market

Return vs Industry: VIFN exceeded the Swiss Pharmaceuticals industry which returned 18.9% over the past year.

Return vs Market: VIFN exceeded the Swiss Market which returned -2.5% over the past year.

Price Volatility

Is VIFN's price volatile compared to industry and market?
VIFN volatility
VIFN Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.9%
10% most volatile stocks in CH Market8.6%
10% least volatile stocks in CH Market2.5%

Stable Share Price: VIFN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: VIFN's weekly volatility (4%) has been stable over the past year.

About the Company

18722,200Shah Hussain

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD) It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis.

Vifor Pharma Fundamentals Summary

How do Vifor Pharma's earnings and revenue compare to its market cap?
VIFN fundamental statistics
Market CapCHF11.00b
Earnings (TTM)CHF146.60m
Revenue (TTM)CHF1.81b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VIFN income statement (TTM)
Cost of RevenueCHF671.80m
Gross ProfitCHF1.14b
Other ExpensesCHF993.70m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 04, 2022

Earnings per share (EPS)2.26
Gross Margin62.93%
Net Profit Margin8.09%
Debt/Equity Ratio13.6%

How did VIFN perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Vifor Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: VIFN (CHF169.5) is trading below our estimate of fair value (CHF458.5)

Significantly Below Fair Value: VIFN is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: VIFN is poor value based on its Price-To-Earnings Ratio (75x) compared to the European Pharmaceuticals industry average (20.3x).

PE vs Market: VIFN is poor value based on its Price-To-Earnings Ratio (75x) compared to the Swiss market (17.9x).

Price to Earnings Growth Ratio

PEG Ratio: VIFN is poor value based on its PEG Ratio (3.6x)

Price to Book Ratio

PB vs Industry: VIFN is overvalued based on its Price-To-Book Ratio (3.2x) compared to the XE Pharmaceuticals industry average (2.5x).

Future Growth

How is Vifor Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score


Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIFN's forecast earnings growth (20.6% per year) is above the savings rate (-0.3%).

Earnings vs Market: VIFN's earnings (20.6% per year) are forecast to grow faster than the Swiss market (5.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VIFN's revenue (8.6% per year) is forecast to grow faster than the Swiss market (4.3% per year).

High Growth Revenue: VIFN's revenue (8.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: VIFN's Return on Equity is forecast to be low in 3 years time (11.5%).

Past Performance

How has Vifor Pharma performed over the past 5 years?

Past Performance Score


Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VIFN has high quality earnings.

Growing Profit Margin: VIFN's current net profit margins (8.1%) are higher than last year (7.9%).

Past Earnings Growth Analysis

Earnings Trend: VIFN's earnings have grown by 16.3% per year over the past 5 years.

Accelerating Growth: VIFN's earnings growth over the past year (5.7%) is below its 5-year average (16.3% per year).

Earnings vs Industry: VIFN earnings growth over the past year (5.7%) underperformed the Pharmaceuticals industry 16.4%.

Return on Equity

High ROE: VIFN's Return on Equity (6.7%) is considered low.

Financial Health

How is Vifor Pharma's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: VIFN's short term assets (CHF1.9B) exceed its short term liabilities (CHF981.3M).

Long Term Liabilities: VIFN's short term assets (CHF1.9B) exceed its long term liabilities (CHF149.2M).

Debt to Equity History and Analysis

Debt Level: VIFN has more cash than its total debt.

Reducing Debt: VIFN's debt to equity ratio has reduced from 86.5% to 13.6% over the past 5 years.

Debt Coverage: VIFN's debt is well covered by operating cash flow (97.6%).

Interest Coverage: VIFN earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet


What is Vifor Pharma current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: VIFN's dividend (1.18%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.92%).

High Dividend: VIFN's dividend (1.18%) is low compared to the top 25% of dividend payers in the Swiss market (3.91%).

Stability and Growth of Payments

Stable Dividend: VIFN's dividends per share have been stable in the past 10 years.

Growing Dividend: VIFN's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: At its current payout ratio (88.5%), VIFN's payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (31.3%), VIFN's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Shah Hussain (56 yo)





Mr. Shah Abbas Hussain, B.Sc. (Hons), serves as Chief Executive Officer at Vifor Pharma AG since August 16, 2021. He serves as Senior Partner at CBC Group (formerly known as C-Bridge Capital Partners LLC)....

CEO Compensation Analysis

Compensation vs Market: Shah's total compensation ($USD3.12M) is below average for companies of similar size in the Swiss market ($USD4.91M).

Compensation vs Earnings: Insufficient data to compare Shah's compensation with company performance.

Leadership Team

Experienced Management: VIFN's management team is seasoned and experienced (6.3 years average tenure).

Board Members

Experienced Board: VIFN's board of directors are considered experienced (3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Vifor Pharma AG's employee growth, exchange listings and data sources

Key Information

  • Name: Vifor Pharma AG
  • Ticker: VIFN
  • Exchange: SWX
  • Founded: 1872
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CHF10.999b
  • Shares outstanding: 64.89m
  • Website:

Number of Employees


  • Vifor Pharma AG
  • Rechenstrasse 37
  • Sankt Gallen
  • St. Gallen
  • 9014
  • Switzerland


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/26 00:00
End of Day Share Price2022/05/25 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.